USA - NASDAQ:ABVC - US00091F3047 - Common Stock
The current stock price of ABVC is 2.99 USD. In the past month the price increased by 3.1%. In the past year, price increased by 498%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA US
CEO: Howard Doong
Employees: 16
Phone: 15106680881
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
The current stock price of ABVC is 2.99 USD. The price increased by 3.46% in the last trading session.
ABVC does not pay a dividend.
ABVC has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
ABVC stock is listed on the Nasdaq exchange.
ABVC BIOPHARMA INC (ABVC) currently has 16 employees.
ABVC BIOPHARMA INC (ABVC) has a market capitalization of 70.38M USD. This makes ABVC a Micro Cap stock.
ChartMill assigns a technical rating of 8 / 10 to ABVC. When comparing the yearly performance of all stocks, ABVC is one of the better performing stocks in the market, outperforming 98.97% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to ABVC. Both the profitability and financial health of ABVC have multiple concerns.
Over the last trailing twelve months ABVC reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 77.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.44% | ||
| ROE | -34.14% | ||
| Debt/Equity | 0.07 |